Johnson & Johnson (NYSE:JNJ) Shares Sold by Carret Asset Management LLC

Carret Asset Management LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,188 shares of the company’s stock after selling 3,233 shares during the period. Johnson & Johnson comprises 1.3% of Carret Asset Management LLC’s portfolio, making the stock its 13th largest position. Carret Asset Management LLC’s holdings in Johnson & Johnson were worth $12,031,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Northwest Wealth Management LLC increased its stake in shares of Johnson & Johnson by 19.3% in the fourth quarter. Northwest Wealth Management LLC now owns 2,362 shares of the company’s stock worth $342,000 after buying an additional 382 shares during the last quarter. Renasant Bank increased its stake in shares of Johnson & Johnson by 12.4% in the fourth quarter. Renasant Bank now owns 3,943 shares of the company’s stock worth $570,000 after buying an additional 436 shares during the last quarter. King Wealth Management Group increased its stake in shares of Johnson & Johnson by 2.1% in the fourth quarter. King Wealth Management Group now owns 15,558 shares of the company’s stock worth $2,250,000 after buying an additional 314 shares during the last quarter. Blume Capital Management Inc. increased its stake in shares of Johnson & Johnson by 4.3% in the fourth quarter. Blume Capital Management Inc. now owns 67,808 shares of the company’s stock worth $9,806,000 after buying an additional 2,777 shares during the last quarter. Finally, May Barnhard Investments LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $379,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

JNJ stock opened at $162.93 on Friday. The company has a market capitalization of $392.28 billion, a P/E ratio of 24.50, a PEG ratio of 2.56 and a beta of 0.47. The company has a 50-day simple moving average of $154.60 and a 200 day simple moving average of $156.38. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.29 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Analyst Ratings Changes

JNJ has been the subject of several recent research reports. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Monday. Stifel Nicolaus lowered their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Bank of America boosted their target price on shares of Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research note on Wednesday, March 5th. Wells Fargo & Company lowered their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, Leerink Partners lowered their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.